PARP and PARG inhibitors--new therapeutic targets in cancer treatment. - Wikidata - awgldk - TriplyDB

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

http://www.wikidata.org/entity/Q37728981

about

Structures of the Human Poly (ADP-Ribose) Glycohydrolase Catalytic Domain Confirm Catalytic Mechanism and Explain Inhibition by ADP-HPD Derivatives Loss of TRPM2 function protects against irradiation-induced salivary gland dysfunction Comparative toxicogenomic responses of mercuric and methyl-mercury.TRPM2: a multifunctional ion channel for calcium signalling.Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.Insight into the machinery that oils chromatin dynamics.Novel hydrophilic docetaxel (CQMU-0519) analogue inhibits proliferation and induces apoptosis in human A549 lung, SKVO3 ovarian and MCF7 breast carcinoma cell lines.Hydrogen peroxide modulates synaptic transmission in ventral horn neurons of the rat spinal cord.Silencing Poly (ADP-Ribose) glycohydrolase (PARG) expression inhibits growth of human colon cancer cells in vitro via PI3K/Akt/NFκ-B pathway.

P2860

Q27675530-666CBB0B-9E7F-45A4-B61E-79A221A3A231 Q33761517-205491E6-D69D-44B4-ACCF-2402AEDFC957 Q35015733-F048B630-A919-48AE-AFAD-7CF9D453C801 Q37816751-E9F62D8F-96D7-46B1-BF63-CD634688E4B2 Q38191981-37A757D5-859F-43C2-A736-1640A0072CF9 Q38789935-A93AA32A-DD73-4460-A8EB-1578C43C965D Q39336275-E4570C42-1A38-4DB7-9478-F6053D3BEFB5 Q46647562-A9B42FE3-6494-4158-A040-49DE16BC2480 Q53237156-6FD7058A-100E-4556-AD23-471857E92D8F

P2860

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

http://www.wikidata.org/entity/Q37728981

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 April 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

@en

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

@nl

type

label

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

@en

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

@nl

prefLabel

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

@en

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

@nl

P1433

Q37728981-A5B97856-AA33-4D24-A6DB-2466CA4C3024

P1476

Q37728981-201D5800-6B98-4B2D-899C-0B9B82946095

P2093

Q37728981-3CB6BE5B-1D52-4531-B390-4652EAD7A66B

Q37728981-BA7DE837-B31A-47F7-852F-92BDCF06EDA2

Q37728981-BCA23C58-A06D-4977-A691-019EE6893BCA

P2860

Q37728981-7E3F9D38-DB9C-463C-9AC2-473582AEE6FA

Q37728981-8512F3F0-3298-479C-B0ED-3DB54FD4BBFA

Q37728981-8E3D238E-056A-4AB2-B80A-372242D3AEF5

Q37728981-956F7838-7A0D-4F41-8A9A-74634D747962

Q37728981-9DCF040F-94A1-4693-A769-EEFD91A37254

Q37728981-BFEB0B8C-E1DC-418C-93DF-29C5E7BA0C88

Q37728981-C75C3A37-300D-4FA2-BCD5-1DE83EFD5FC3

Q37728981-D1C8658B-19B1-431B-89B1-535647961E6C

Q37728981-D3278193-E76A-4587-A954-BDC1C5709B43

Q37728981-E28DA799-C446-40AE-86EB-B45B537EB331

P2888

Q37728981-02628578-22AB-4336-9BA5-83A3F82B2243

P304

Q37728981-E9B1A054-C10B-4EC2-AEF5-EBE952C2E248

P31

Q37728981-144429F2-203E-439E-90B9-5C73A52F39E4

P356

Q37728981-FB9F9258-3821-4B02-8D8A-35C4927B986C

P433

Q37728981-C3EDDF65-FB60-40F3-AFF2-3C6E4E464F7C

P478

Q37728981-54DD5BAB-F203-455A-A343-FEC289DE7ADF

P577

Q37728981-46530992-10C8-4C7F-8BB5-79789044EF60

P698

Q37728981-D7FC88FE-C3F2-4791-ACB0-6F14AFF7A35B

P356

S12253-010-9266-6

P1433

Pathology Oncology Research

P1476

PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

@en

P2093

Juan Pan

http://www.w3.org/2001/XMLSchema#string

Nilufer Jasmine Selimah Fauzee

http://www.w3.org/2001/XMLSchema#string

Ya-lan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Novel inhibitors of poly(ADP-ribose) synthetase

Early embryonic lethality in PARP-1 Atm double-mutant mice suggests a functional synergy in cell proliferation during development

Poly(ADP-ribose) polymerase binds with transcription enhancer factor 1 to MCAT1 elements to regulate muscle-specific transcription

Role of angiogenesis in tumor growth and metastasis

The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

PARP inhibitors for cancer therapy.

Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase

Modulation of poly(ADP-ribose) polymerase during neutrophilic and monocytic differentiation of promyelocytic (NB4) and myelocytic (HL-60) leukaemia cells.

Medulloblastoma in mice lacking p53 and PARP: all roads lead to Gli.

P2888

s12253-010-9266-6

P304

469-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12253-010-9266-6

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20383759

http://www.w3.org/2001/XMLSchema#string